http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
우루시올-에탄올 수분산 미립자의 자궁경부암세포에 대한 독성효과
김진우,유규은,장홍석,인웅식,최종오,전흥재 한국약제학회 2004 Journal of Pharmaceutical Investigation Vol.34 No.1
The urushiol-ethanol corpuscle of 320 nM in average particle size was prepared and concentrated by ultra homogenization and centrifugation. The cytotoxic profiles of this particle for use as anti-tumor agent have been evaluated in vitro in cultures of human fibroblasts (MRC-9) and celivical cacinoma cells (CUMC-3). The cytotoxicity assays revealed that the inhibitory effect of 10^(-5)M usushiol-ethanol particle on the growth of MRC-9 was hardly detected, while CUMC-3 dells exhibited over 50% of growth inhibition under the same conditions. In addition, a clear multiple-unit ladder pattern of apoptotic DNA was observed for the urushiol treated CUMC-3 cells. Thus, the results indicated that urushiol inhibited growth of celvical carcinoma cells by inducing apoptosis, which is a mechanism observed with other typical antitumor agents.
아크릴산 및 아크릴아미드에 의하여 표면처리된 PMMA 인공수정체의 세포 및 조직적합성
김만수,채규태,전흥재,신은미,유창국,이종헌,이무석,유규은 한국생체재료학회 2004 생체재료학회지 Vol.8 No.1
Surface modified polymethyl methacrylate intra ocular lenses (PMMA IOLs) with acrylic acid (AAc) and acrylamide (AAm) were prepared via plasma-induced graft polymerization. The biocompatibility profiles of these IOLs have been evaluated (i) in vitro in cultures of mouse fibroblasts, and (ii) in vivo by subcutaneous implantation studies in rats. A cytotoxicity assay revealed that PMMA-g-AAc IOLs had very low cytotoxicity which were similar to that of control PMMA IOLs. Subcutaneous implantation studies in rats showed that both PMMA-g-AAc and PMMA-g-AAm IOLs created the delayed foreign body reactions compared to control PMMA IOLs. However, no severe acute foreign body reactions were found around the implants, and these reactions became shrunk upon increasing implantation time. These results suggest that surface treatment PMMA IOLs with hydrophilic acrylic monomers are promising in the design of IOLs for inhibition or retardation of recurrence of after cataract.